Full-Time
Quality Control Inspector 2
Cooper Companies
201-500 employees
Global medical devices and vision care
No salary listed
Bridgeport, CT, USA
In Person
 QA & Testing (2) |
|---|
| , |
Get referred to Cooper Companies
See people who can refer or advise you
- Working knowledge of cGMP, FDA quality system regulations, and quality inspection practices in a regulated environment.
- Ability to interpret drawings, specifications, and inspection methods.
- Working knowledge of 21 CFR 820, ISO 13485, EU MDR, MDSAP, and other global standards
- Experience and ability in reading and interpreting engineering drawings.
- Proficiency using inspection tools and measuring equipment.
- Experience using vision systems and other automated inspection systems.
- Strong attention to detail and accuracy.
- Strong organizational, interpersonal, verbal, and written communication skills (clear, concise, effective with a variety of stakeholders).
- Must be proficient in the use of Microsoft Excel, Microsoft Word, Outlook, and PowerPoint.
- Strong organizational, troubleshooting, and problem-solving skills.
- Perform routine and detailed inspections of incoming materials, in-process goods, and finished products.
- Conduct visual, dimensional, mechanical, and functional inspection using approved methods, tools, and equipment.
- Ensure components, subassemblies, and finished products comply with approved company drawings and specifications.
- Document inspection results to ensure full traceability.
- Identify, document, and report defects or nonconformances (NCMRs)
- Provide guidance for less experienced team members
- Support Site Quality Management in determining disposition of product (accept, reject, rework, return to vendor) in accordance with approved company procedures.
- Collaborate cross-functionally to assist with investigations and resolve potential quality issues.
- Support corrective and preventive action (CAPA) activities.
- Participate in internal and external audits and inspections as required.
- Participate in other projects as required by Quality Management.
- Perform other duties as assigned.
Cooper Companies operates in two main areas: CooperVision and CooperSurgical. CooperVision makes a wide range of contact lenses to correct vision, supported by product development, manufacturing, and global distribution. CooperSurgical offers medical devices, fertility, and genomic products for women’s health, covering care from contraception through advanced reproductive treatments, with a vertically integrated model that controls research, development, manufacturing, and distribution. Compared with competitors, the company combines vision care and women’s health in one group and maintains end-to-end control of its product lifecycle, enabling integrated supply and service delivery to healthcare providers and patients worldwide. Its goal is to improve health outcomes for people through accessible contact lenses and comprehensive women’s health products and services, across the globe.
Company Size
201-500
Company Stage
IPO
Headquarters
Pleasanton, California
Founded
1958
Get referred to Cooper Companies
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue reached $1.082 billion, up 8%, with CooperVision and CooperSurgical both growing.
- Management lifted 2026 revenue guidance to $4.285-$4.321 billion on March 5 and June 4.
- Fertility business grew 13% organically in Q2 2026, signaling post-recall recovery.
What critics are saying
- June 4, 2026 litigation charges cut GAAP EPS to $(0.40) and hit SG&A.
- The December 2023 CooperSurgical recall spawned 140-plus lawsuits and 1,500 claimants by June 2026.
- If recall liabilities outrun insurance, CooperSurgical’s fertility franchise becomes a capital drain.
What makes Cooper Companies unique
- MiSight remains the only FDA-approved myopia-control contact lens, with Japan authorization in February 2026.
- MyDay’s premium silicone-hydrogel rollout drives share gains across EMEA, Americas, and Asia-Pacific.
- CooperSurgical combines fertility devices, lab tracking, and women’s-health products under one platform.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Paid Vacation
Performance Bonus
Health Insurance
401(k) Retirement Plan
Life Insurance
Wellness Program
Professional Development Budget
Company News
The Cooper Companies reported total revenue of $1.08 billion for the quarter ending April 2026, up 7.9% year over year. International markets contributed significantly to this performance, with EMEA generating $289.7 million (26.8% of total revenue) and Asia Pacific adding $130.6 million (12.1%). EMEA revenue exceeded Wall Street expectations by 5.18%, whilst Asia Pacific fell marginally short by 0.17%. The surgical and contact lens products maker's EMEA performance represented growth from $248.6 million in the year-ago quarter, though Asia Pacific revenue declined from $138.6 million over the same period. For the current fiscal quarter, analysts project total revenue of $1.12 billion, with EMEA expected to contribute $305.46 million and Asia Pacific $143.73 million.
The Cooper Companies reported a fiscal Q2 loss of $77.9 million, or 40 cents per share. However, adjusted earnings came to $1.21 per share, exceeding Wall Street expectations of $1.10 per share. The San Ramon, California-based surgical and contact lens products maker posted revenue of $1.08 billion, beating analyst forecasts of $1.05 billion. For the full year, the company expects earnings between $4.58 and $4.66 per share, with revenue ranging from $4.29 billion to $4.32 billion.
CooperCompanies has appointed Paul Keel as an independent director to its board, effective 1 July 2026. He will also serve on the Audit Committee. Keel currently serves as President and Chief Executive Officer of Envista Holdings Corporation, a global specialty medical technology company, since 2024. Previously, he was CEO of Smiths Group plc from 2021 to 2024 and spent 16 years at 3M in various leadership roles, including Group President of 3M Consumer Business and President of 3M Medical. CooperCompanies is a global medical device company operating through two business units, CooperVision and CooperSurgical, serving over 130 countries with a workforce exceeding 15,000 people.
CooperCompanies appoints Paul Keel to its Board of Directors. GlobeNewswire | CooperCompanies Yesterday at 1:15pm PDT SAN RAMON, Calif., May 04, 2026 (GLOBE NEWSWIRE) - CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today that its Board of Directors has appointed Paul Keel as an independent director, effective July 1, 2026. Mr. Keel has also been appointed to serve on the Audit Committee when he joins the Board. "We are delighted to welcome Paul to our Board as a new Director," said Colleen Jay, Chair of the Board of CooperCompanies. "His experience as a CEO in the medical device sector, along with a successful track record of leading complex global operations, will be a significant asset as Cooper continues to execute its strategy and create long-term value for patients, customers, and shareholders." Mr. Keel has served as President and Chief Executive Officer of Envista Holdings Corporation (NYSE: NVST), a global specialty medical technology company, since 2024. Prior to joining Envista, Mr. Keel served as CEO of Smiths Group plc (LON: SMIN), a diversified global industrial technology company and FTSE constituent, from 2021 to 2024. Earlier, he spent 16 years at 3M, serving in various leadership roles, including Group President of 3M Consumer Business, President of 3M Medical, President of 3M Unitek, SVP of Manufacturing & Supply Chain, and SVP of Marketing, Sales & Business Development. Mr. Keel's career also includes roles at General Mills, General Electric, Norwest Equity Partners, and McKinsey & Company. He holds an MBA from Harvard Business School and a BA in Economics from Carleton College. About CooperCompanies CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women's healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com. Forward-Looking Statements This press release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to the Company's efforts to enhance long-term shareholder value, plans, strategies, future actions, and other statements of which are other than statements of historical fact, are forward-looking. Forward-looking statements necessarily depend on assumptions, data, or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Statements regarding future events and performance and contain words such as "expects" and similar words or phrases. A wide range of factors could materially affect future developments, including, but not limited to, uncertainties related to market conditions and other factors set forth in its other filings with the United States Securities and Exchange Commission, including its most recent Annual Report on Form 10-K. These risks and uncertainties may cause actual future results or actions to be materially different than those expressed in such forward-looking statements. Oregon Capital Insider do not intend, or undertake any duty, to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Kim Duncan Vice President, Investor Relations and Risk Management 925-460-3663 This is a paid placement. For further inquiries, please contact GlobeNewswire directly.
Cooper Companies has raised $120 million in a Series C round, valuing the healthcare company at $1.45 billion, as shares face recent pressure with declines of 9% over the past month and roughly 17% over three months. The company operates two main businesses: CooperVision, generating revenue of $2.79 billion from contact lenses, and CooperSurgical, contributing $1.36 billion from women's and family health products. Total annual revenue reached $4.15 billion with net income of $401.4 million. Recent analysis suggests the stock may be 24.1% undervalued at its current price of $69.66, with a fair value estimate of $91.80. Management projects approximately $2 billion in free cash flow over the next three years as capital expenditure cycles wind down.